Glenmark Pharma launches Ryaltris in USGLENMARK - 770 Change: -1.10 (-0.14 %)
News: Hikma Pharma and Glenmark Pharma have launched Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. Ryaltris is approved by USFDA for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and paediatric patients 12 years of age and older. Ryaltris is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray.
View: Ryaltris is the first global branded specialty product to be marketed in the US by Glenmark Pharma. This launch is a major milestone for Glenmark, which demonstrates the focus in strengthening global respiratory leadership. About 60 million Americans suffer from allergic rhinitis and allergic conjunctivitis and in partnership with Hikma allows to leverage its strong, existing specialty salesforce for this new treatment option. Additionally, Glenmark has extensive plans to strengthen its respiratory franchise with the launch of Ryaltris in multiple markets in FY23. Overall, Glenmark is expected to grow revenues at CAGR of 7% over FY22-24E with the company focused on sustaining current EBITDA margins of 19% and debt reduction.